Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.35 USD | +4.90% |
|
-3.26% | -61.38% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.45 times its sales.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-61.38% | 29Cr | C+ | ||
-4.11% | 18TCr | C+ | ||
-3.00% | 10TCr | C | ||
-4.67% | 6.76TCr | A | ||
+15.59% | 4.69TCr | B- | ||
-9.37% | 4.39TCr | B- | ||
+8.28% | 4.12TCr | B+ | ||
+17.43% | 3.05TCr | B | ||
+13.59% | 2.42TCr | A- | ||
-7.22% | 2.36TCr | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NVRO Stock
- Ratings Nevro Corp.